142 related articles for article (PubMed ID: 38194688)
1. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I; Zaghi M; Mastini C; D'Aliberti D; Mauri M; Mercado CM; Fontana D; Spinelli S; Crippa V; Inzoli E; Manghisi B; Civettini I; Ramazzotti D; Sangiorgio V; Gengotti M; Brambilla V; Aroldi A; Banfi F; Barone C; Orsenigo R; Riera L; Riminucci M; Corsi A; Breccia M; Morotti A; Cilloni D; Roccaro A; Sacco A; Stagno F; Serafini M; Mottadelli F; Cazzaniga G; Pagni F; Chiarle R; Azzoni E; Sessa A; Gambacorti-Passerini C; Elli EM; Mologni L; Piazza R
Blood; 2024 Apr; 143(14):1399-1413. PubMed ID: 38194688
[TBL] [Abstract][Full Text] [Related]
2. Somatic SETBP1 mutations in myeloid malignancies.
Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
[TBL] [Abstract][Full Text] [Related]
3. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
[TBL] [Abstract][Full Text] [Related]
4. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
5. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
6. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
[TBL] [Abstract][Full Text] [Related]
7. Somatic SETBP1 mutations in myeloid neoplasms.
Makishima H
Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
[TBL] [Abstract][Full Text] [Related]
8. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
10. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
11. SETBP1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Yao XY; Zhou JD; Yang J; Zhang W; Ma JC; Wen XM; Yao DM; Xu ZJ; Wu DH; He PF; Qian J; Lin J
Pathol Res Pract; 2018 May; 214(5):706-712. PubMed ID: 29549983
[TBL] [Abstract][Full Text] [Related]
12. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract][Full Text] [Related]
13. SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia.
Albano F; Anelli L; Zagaria A; Coccaro N; Casieri P; Minervini A; Specchia G
J Hematol Oncol; 2012 Aug; 5():48. PubMed ID: 22873195
[TBL] [Abstract][Full Text] [Related]
14. Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
Alvarez-Larrán A; López-Guerra M; Rozman M; Correa JG; Hernández-Boluda JC; Tormo M; Martínez D; Martín I; Colomer D; Esteve J; Cervantes F
Ann Hematol; 2019 Oct; 98(10):2319-2328. PubMed ID: 31396671
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
[TBL] [Abstract][Full Text] [Related]
16. Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.
Nguyen N; Vishwakarma BA; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
Oncotarget; 2016 Dec; 7(52):86300-86312. PubMed ID: 27863435
[TBL] [Abstract][Full Text] [Related]
17. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
18. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
Bonnet S; Carillo S; Legrand B; Burroni B; Lavabre-Bertrand T; Requirand G; Robert N; Fornero L; Al Mansoori A; Moreaux J; Cartron G; Gabellier L; Herbaux C
Eur J Haematol; 2024 Mar; 112(3):475-478. PubMed ID: 37918825
[TBL] [Abstract][Full Text] [Related]
19. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
20. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
